ZNTL analyst estimates
Zentalis (ZNTL) analyst ratings, the average price target and its range, and every firm's latest call.
- 3 firms rate ZNTL: 3 buy, 0 hold, 0 sell.
- The average price target is $7.25 from None analysts, from $5.00 to $10.00.
ZNTL analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Nov 10, 2026 | Wedbush | Wedbush Upgrades Zentalis Pharmaceuticals (ZNTL) to Outperform | $6.00 |
| Oct 5, 2026 | Leerink Partners | Zentalis assumed at Outperform from Market Perform at Leerink | $8.00 |
| Aug 7, 2026 | Morgan Stanley | Zentalis price target raised to $5 from $4 at Morgan Stanley | $5.00 |
| May 22, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL) | $10.00 |
| Apr 10, 2026 | Guggenheim | Zentalis price target raised to $10 from $6 at Guggenheim | $10.00 |
| Nov 11, 2025 | Leerink Partners | Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2 at Leerink Partners | $2.00 |
| Jun 18, 2024 | Wedbush | Wedbush downgrades Zentalis to Underperform on unclear azeno path forward | $4.00 |
| Jun 18, 2024 | Stifel Nicolaus | Zentalis price target lowered to $10 from $32 at Stifel | $10.00 |
| Jun 18, 2024 | Morgan Stanley | Morgan Stanley Downgrades Zentalis Pharmaceuticals (ZNTL) to Equalweight | $8.00 |
| Jun 18, 2024 | Jefferies | Zentalis downgraded to Hold from Buy at Jefferies | $6.00 |
| May 7, 2024 | Stifel Nicolaus | Zentalis Pharmaceuticals (ZNTL) PT Lowered to $32 at Stifel | $32.00 |
| Nov 14, 2022 | Wedbush | Wedbush Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $32 | $32.00 |
| Nov 11, 2022 | Guggenheim | Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Lowers Price Target to $28 | $28.00 |
| Nov 11, 2022 | Morgan Stanley | Morgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Lowers Price Target to $55 | $55.00 |
| Aug 10, 2022 | Leerink Partners | SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $42 | $42.00 |